Subunit respiratory syncytial virus vaccine preparation
US6309649A · kind A · utility
4Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 3, 1999 |
| Grant date | Oct 30, 2001 |
| Priority date | — |
| Expiry date | May 3, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18551
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) are isolated and purified from respiratory syncytial virus by mild detergent extraction of the proteins from concentrated virus, loading the protein onto a hydroxyapatite or other ion-exchange matrix column and eluting the protein using mild salt treatment. The F, G and M proteins, formulated as immunogenic compositions, are safe and highly immunogenic and protect relevant animal models against decreased caused by respiratory syncytial virus infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.